Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis

Psoriasis is a chronic papulosquamous skin disease with an autoimmune pathogenic traits and strong genetic predisposition. In the past few decades, with the rapid development of molecular biology and cell biology, the inherent pathogenesis of psoriasis has been gradually elucidated, in which cytokine inflammatory loops, cell signaling pathways, and epigenetic factors such as miRNAs have been demonstrated to play important roles in regulating the development and progression of psoriasis. More importantly, understanding the pathogenesis of psoriasis has promoted the development of effective treatment for psoriasis. In this review, we systemically summarized the molecular mechanisms regulating the development and progression psoriasis, introduced various therapeutics used for clinical psoriasis therapy, and highlighted the recent advances in nanoparticles (NPs)-mediated drug delivery for psoriasis treatment.

[1]  Chenjie Xu,et al.  Design principles of microneedles for drug delivery and sampling applications , 2022, Materials Today.

[2]  Yuanjin Zhao,et al.  Biologics‐Loaded Photothermally Dissolvable Hyaluronic Acid Microneedle Patch for Psoriasis Treatment , 2022, Advanced Functional Materials.

[3]  Teng Shen,et al.  Tacrolimus nanocrystals microneedle patch for plaque psoriasis. , 2022, International journal of pharmaceutics.

[4]  Huacheng He,et al.  Latest on biomaterial-based therapies for topical treatment of psoriasis. , 2022, Journal of materials chemistry. B.

[5]  B. Cheng,et al.  A Modified Hyaluronic Acid–Based Dissolving Microneedle Loaded With Daphnetin Improved the Treatment of Psoriasis , 2022, Frontiers in Bioengineering and Biotechnology.

[6]  Ruijie Chen,et al.  Alantolactone-loaded chitosan/hyaluronic acid nanoparticles suppress psoriasis by deactivating STAT3 pathway and restricting immune cell recruitment , 2022, Asian journal of pharmaceutical sciences.

[7]  Haiyan Jia,et al.  Par3 regulates the asymmetric division of basal stem cells in psoriasis via the Par3/mInsc/LGN signaling axis. , 2022, Cellular immunology.

[8]  E. Papadavid,et al.  Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential , 2022, International journal of molecular sciences.

[9]  C. H. J. Choi,et al.  Alkyl-Terminated Gold Nanoparticles as a Self-Therapeutic Treatment for Psoriasis. , 2021, Nano letters.

[10]  V. Sobolev,et al.  Analysis of PPARγ Signaling Activity in Psoriasis , 2021, International journal of molecular sciences.

[11]  T. Torres,et al.  Bimekizumab: the new drug in the biologics armamentarium for psoriasis , 2021, Drugs in context.

[12]  E. Sánchez-López,et al.  Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics , 2021, International journal of molecular sciences.

[13]  Yu Wang,et al.  Emerging Functional Biomaterials as Medical Patches. , 2021, ACS nano.

[14]  Y. Ping,et al.  Microneedle-assisted genome editing: A transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders , 2021, Science Advances.

[15]  T. Gambichler,et al.  Increased expression profile of NCSTN, Notch and PI3K/AKT3 in hidradenitis suppurativa , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  K. Schäkel,et al.  The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. , 2020, The Journal of clinical investigation.

[17]  Ming-zhu Yin,et al.  miR-205-5p inhibits psoriasis-associated proliferation and angiogenesis: Wnt/β-catenin and mitogen-activated protein kinase signaling pathway are involved. , 2020, The Journal of dermatology.

[18]  M. Obeidat,et al.  IL-33/13 Axis and IL-4/31 Axis Play Distinct Roles in Inflammatory Process and Itch in Psoriasis and Atopic Dermatitis , 2020, Clinical, cosmetic and investigational dermatology.

[19]  Wei Zhao,et al.  Cimifugin ameliorates imiquimod-induced psoriasis by inhibiting oxidative stress and inflammation via NF-κB/MAPK pathway , 2020, Bioscience reports.

[20]  Kaiming Zhang,et al.  Different epigenome regulation and transcriptome expression of CD4+ and CD8+ T cells from monozygotic twins discordant for psoriasis , 2020, The Australasian journal of dermatology.

[21]  P. Bolfa,et al.  Modulatory effects of Cornus sanguinea L. mediated green synthesized silver nanoparticles on oxidative stress, COX-2/NOS2 and NFkB/pNFkB expressions in experimental inflammation in Wistar rats. , 2020, Materials science & engineering. C, Materials for biological applications.

[22]  C. Gabay,et al.  IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis , 2020, Life Science Alliance.

[23]  L. Dobrucki,et al.  Pathogenesis of psoriasis in the “omic” era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances , 2020, Postepy dermatologii i alergologii.

[24]  A. Grossman,et al.  Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases , 2021, Arthritis care & research.

[25]  C. Akdis,et al.  Nanoparticle-coupled topical methotrexate can normalize immune responses and induce tissue remodeling in psoriasis. , 2020, The Journal of investigative dermatology.

[26]  Upendra Bulbake,et al.  Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis , 2019, Journal of liposome research.

[27]  Q. Lu,et al.  Topical administration of nanocarrier miRNA‐210 antisense ameliorates imiquimod‐induced psoriasis‐like dermatitis in mice , 2019, The Journal of dermatology.

[28]  Jinjin Zhu,et al.  Hyaluronic Acid Dissolving Microneedle Patch Loaded with Methotrexate for Improved Treatment of Psoriasis. , 2019, ACS applied materials & interfaces.

[29]  Guanglin Zhang,et al.  FGF-7 facilitates the process of psoriasis by inducing TNF-α expression in HaCaT cells. , 2019, Acta biochimica et biophysica Sinica.

[30]  Yingyuan Yu,et al.  IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients , 2019, Front. Immunol..

[31]  Xiaoyun Yu,et al.  FGF19 sustains the high proliferative ability of keratinocytes in psoriasis through the regulation of Wnt/GSK‐3β/β‐catenin signalling via FGFR4 , 2019, Clinical and experimental pharmacology & physiology.

[32]  T. Beikler,et al.  Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases , 2019, International journal of molecular sciences.

[33]  D. Kalvakolanu,et al.  IL-33 contributes to disease severity in Psoriasis-like models of mouse. , 2019, Cytokine.

[34]  Özgür Gündüz JAK/STAT pathway modulation: Does it work in dermatology? , 2019, Dermatologic therapy.

[35]  Adriana Rendon,et al.  Psoriasis Pathogenesis and Treatment , 2019, International journal of molecular sciences.

[36]  R. Weichselbaum,et al.  A Critical Role of the IL-1β-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. , 2019, The Journal of investigative dermatology.

[37]  E. Halilovic,et al.  Serum Concentrations of Interferon Gamma (IFN-γ) in Patients with Psoriasis: Correlation with Clinical Type and Severity of the Disease , 2018, Medical archives.

[38]  C. Buerger Epidermal mTORC1 Signaling Contributes to the Pathogenesis of Psoriasis and Could Serve as a Therapeutic Target , 2018, Front. Immunol..

[39]  J. Krueger,et al.  Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis , 2018, The Journal of Immunology.

[40]  Liangdan Sun,et al.  NFKB1 mediates Th1/Th17 activation in the pathogenesis of psoriasis. , 2018, Cellular immunology.

[41]  Qing Sun,et al.  miR-320b Is Down-Regulated in Psoriasis and Modulates Keratinocyte Proliferation by Targeting AKT3 , 2018, Inflammation.

[42]  M. Crisan,et al.  Topical silver and gold nanoparticles complexed with Cornus mas suppress inflammation in human psoriasis plaques by inhibiting NF‐κB activity , 2018, Experimental dermatology.

[43]  Tingting Zheng,et al.  MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease , 2018, Front. Immunol..

[44]  L. Tsoi,et al.  RNA-Seq Analysis of IL-1B and IL-36 Responses in Epidermal Keratinocytes Identifies a Shared MyD88-Dependent Gene Signature , 2018, Front. Immunol..

[45]  K. Ross,et al.  Towards topical microRNA‐directed therapy for epidermal disorders , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[46]  P. Wolf,et al.  Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice. , 2017, Acta dermato-venereologica.

[47]  Jan Kremláček,et al.  Roles of miR-31 and endothelin-1 in psoriasis vulgaris: pathophysiological functions and potential biomarkers. , 2017, Physiological research.

[48]  J. Krueger,et al.  Psoriasis pathogenesis and the development of novel targeted immune therapies , 2017, The Journal of allergy and clinical immunology.

[49]  N. Balato,et al.  Mechanistic target of rapamycin complex 1 is involved in psoriasis and regulated by anti‐TNF‐α treatment , 2017, Experimental dermatology.

[50]  B. King,et al.  JAK inhibitors in dermatology: The promise of a new drug class , 2017, Journal of the American Academy of Dermatology.

[51]  Hao Yin,et al.  Delivery technologies for genome editing , 2017, Nature Reviews Drug Discovery.

[52]  D. Schwartz,et al.  JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects , 2017, Drugs.

[53]  S. Arias-Santiago,et al.  Increased expression of microRNA‐155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[54]  S. John,et al.  A systematic review of worldwide epidemiology of psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[55]  Mandip Singh,et al.  Novel amphiphilic lipid augments the co‐delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[56]  Lisa A. DeLouise,et al.  Nanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control and Tissue Targeting , 2016, Molecules.

[57]  A. Reza,et al.  Effectiveness of Topical Corticosteroid, Topical Calcineurin Inhibitors and Combination of Them in the Treatment of Vitiligo. , 2016, Mymensingh medical journal : MMJ.

[58]  S. Suresh,et al.  A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation , 2015, Pharmaceutical development and technology.

[59]  T. Torres,et al.  Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors , 2016, European Journal of Dermatology.

[60]  Hong Wang,et al.  NF-κB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis , 2015, Nature Communications.

[61]  F. Ahmad,et al.  Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy , 2015, Expert opinion on drug delivery.

[62]  Massimo Gadina,et al.  The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.

[63]  Y. Kalia,et al.  Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[64]  Mandip Singh,et al.  Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. , 2014, Nanomedicine.

[65]  M. Crisan,et al.  Green synthesis, characterization and anti-inflammatory activity of silver nanoparticles using European black elderberry fruits extract. , 2014, Colloids and surfaces. B, Biointerfaces.

[66]  Lone Skov,et al.  MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. , 2014, Journal of dermatological science.

[67]  S. Chimenti,et al.  IL-6 as a Druggable Target in Psoriasis: Focus on Pustular Variants , 2014, Journal of immunology research.

[68]  Mayte Suárez-Fariñas,et al.  Immunology of psoriasis. , 2014, Annual review of immunology.

[69]  D. Bogdanos,et al.  The Role of p38 MAPK in the Aetiopathogenesis of Psoriasis and Psoriatic Arthritis , 2013, Clinical & developmental immunology.

[70]  M. Mahmoudi,et al.  Expression patterns of Th1/Th2 transcription factors in patients with guttate psoriasis. , 2013, Acta microbiologica et immunologica Hungarica.

[71]  Luigi Calzolai,et al.  Gold nanoparticles downregulate interleukin-1β-induced pro-inflammatory responses. , 2013, Small.

[72]  Y. Sakaguchi,et al.  Serum Cytokines Correlated with The Disease Severity of Generalized Pustular Psoriasis , 2013, Disease markers.

[73]  A. Pivarcsi,et al.  MicroRNA-31 Is Overexpressed in Psoriasis and Modulates Inflammatory Cytokine and Chemokine Production in Keratinocytes via Targeting Serine/Threonine Kinase 40 , 2013, The Journal of Immunology.

[74]  M. Suárez-Fariñas,et al.  A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin , 2011, The Journal of investigative dermatology.

[75]  M. Suárez-Fariñas,et al.  Human keratinocytes' response to injury upregulates CCL20 and other genes linking innate and adaptive immunity , 2011, The Journal of investigative dermatology.

[76]  Weixiong Zhang,et al.  Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. , 2011, Human molecular genetics.

[77]  L. Jensen Targeting the IL-1 family members in skin inflammation. , 2010, Current opinion in investigational drugs.

[78]  J. Zhang,et al.  Decreased colony formation of high proliferative potential colony‐forming cells and granulocyte‐macrophage colony‐forming units and increased Hes‐1 expression in bone marrow mononuclear cells from patients with psoriasis , 2010, The British journal of dermatology.

[79]  James T. Elder,et al.  Evidence for altered Wnt signaling in psoriatic skin. , 2010, The Journal of investigative dermatology.

[80]  M. Wittmann,et al.  Interleukin‐1 from epithelial cells fosters T cell‐dependent skin inflammation , 2010, The British journal of dermatology.

[81]  W. Leonard,et al.  Atopic Dermatitis-Like Disease and Associated Lethal Myeloproliferative Disorder Arise from Loss of Notch Signaling in the Murine Skin , 2010, PloS one.

[82]  J. Saurat,et al.  High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice , 2010, Dermatology.

[83]  A. Ishida-Yamamoto,et al.  Serum cytokines and growth factor levels in Japanese patients with psoriasis , 2009, Clinical and experimental dermatology.

[84]  M. Jakobsen,et al.  Amelioration of Psoriasis by Anti-TNF-α RNAi in the Xenograft Transplantation Model. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[85]  I. Faraoni,et al.  miR-155 gene: a typical multifunctional microRNA. , 2009, Biochimica et biophysica acta.

[86]  Chi-Hsien Liu,et al.  Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[87]  A. Rebora Conventional therapies for psoriasis. , 2011, Reumatismo.

[88]  H. Dinh,et al.  Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation , 2007, The Journal of experimental medicine.

[89]  P. Janson,et al.  MicroRNAs: Novel Regulators Involved in the Pathogenesis of Psoriasis? , 2007, PloS one.

[90]  O. Arican,et al.  Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity , 2005, Mediators of inflammation.

[91]  F. Nestle,et al.  Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.

[92]  V. Ambros The functions of animal microRNAs , 2004, Nature.

[93]  D. Bartel,et al.  MicroRNA-Directed Cleavage of HOXB8 mRNA , 2004, Science.

[94]  K. Gordon,et al.  The immunology of psoriasis and biologic immunotherapy. , 2003, Journal of the American Academy of Dermatology.

[95]  Mark Lebwohl,et al.  Psoriasis , 1906, The Lancet.

[96]  W. Jochum,et al.  T cells involved in psoriasis vulgaris belong to the Th1 subset. , 1994, The Journal of investigative dermatology.